RxDoctor Payments Data

Homayoun Siman, MD

General Practice · Palm Desert, CANPI 1477971125

Payments from drug & device makers

$2,983in general payments, 2019–2025

Across 158 payments — averaging $18.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$429
  • Novo Nordisk$390
  • AstraZeneca$260
  • Johnson & Johnson$216
  • Pfizer$211
  • Amarin Pharma, Inc.$190
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$2,971100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,983 in reported general payments places this provider in the 90th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$679,106
Medicare patients
672
Services billed
32,188

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide171$246,766
OzempicSemaglutide108$150,834
EliquisApixaban98$124,649
JardianceEmpagliflozin76$88,367
Synjardy XrEmpagliflozin/Metformin Hcl63$80,016
TrulicityDulaglutide40$58,713
XareltoRivaroxaban40$53,711
FarxigaDapagliflozin Propanediol42$51,639
Diclofenac Sodium85$51,292
GlyxambiEmpagliflozin/Linagliptin27$41,467
Nurtec OdtRimegepant Sulfate14$39,002
Trijardy XrEmpaglifloz/Linaglip/Metformin32$35,636
JanuviaSitagliptin Phosphate21$28,240
ProliaDenosumab16$27,302
Xigduo XrDapaglifloz Propaned/Metformin20$23,328

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$148$305,479211 claims
Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Trijardy Xr, Tradjenta$65$256,820210 claims
PfizerEliquis, Nurtec Odt, Prempro$211$170,137124 claims
Novo NordiskOzempic$390$150,834108 claims
AstraZenecaFarxiga, Breztri Aerosphere$260$66,37660 claims
Johnson & JohnsonXarelto$216$53,71140 claims
MerckJanuvia$105$28,24021 claims
AmgenProlia$429$27,30216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 12,963 general practice providers in California.

Other general practice in Palm Desert

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →